Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft‑versus‑Host Disease (aGvHD) with gastrointestinal ...
Cyprus Mail on MSN
Innovative European LIFE Pharma-Detox project, coordinated by Medochemie, under way
With steady progress and growing international recognition, the European project LIFE Pharma-Detox continues to advance under the coordination of Medochemie, setting a new benchmark for pharmaceutical ...
LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies ...
Copenhagen, Denmark, March 26, 2026-Zealand Pharma A/S ("Zealand Pharma" or the “Company”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today ...
NANTES, France--(BUSINESS WIRE)--Regulatory News: PHERECYDES Pharma (FR0011651694 – ALPHE), a biotechnology company specializing in extended phage therapy for treating antibiotic-resistant and/or ...
Copenhagen, Denmark, May 1, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby ...
• According to customers, the biggest gaps arise from a lack of knowledge surrounding business and market access topics as well as a lack of account team coordination. • Customers recommend training ...
Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026 Copenhagen, Denmark, May 1, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results